Giant pituitary adenomas: Pathologic-radiographic correlations and lack of role for p53 and MIB-1 labeling

American Journal of Surgical Pathology

Volumn 35, Issue 8, 2011, Pages 1204-1213

  Madsen, Helen ^a   Borges, Thomas M ^b   Knox, Aaron J ^b   Michaelis, Katherine A ^b   Xu, Mei ^b   Lillehei, Kevin O ^a   Wierman, Margaret E ^b   Kleinschmidt DeMasters, Bette Kay ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

aggressive; cell cycling; giant prolactinoma; gonadotroph cell adenoma; invasive; MIB 1; microarray; mRNA; p53

Indexed keywords

KI 67 ANTIGEN; MESSENGER RNA; PROTEIN P53; TP53 PROTEIN, HUMAN;

ADENOMA; ADULT; AGED; ARTICLE; CANCER INVASION; CAVERNOUS SINUS; CELL PROLIFERATION; CHEMISTRY; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; GONADOTROPIN SECRETING CELL; HUMAN; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; MALE; METHODOLOGY; MIDDLE AGED; MITOSIS INDEX; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROLACTINOMA; RADIOGRAPHY; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKULL BASE; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE; TUMOR VOLUME;

ADENOMA; ADULT; AGED; CAVERNOUS SINUS; CELL PROLIFERATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GONADOTROPHS; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MITOTIC INDEX; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PITUITARY NEOPLASMS; PROLACTINOMA; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKULL BASE; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79961040546     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31821e8c96     Document Type: Article

References (23)

1. Asa SL. Practical pituitary pathology: what does the pathologist need to know? Arch Pathol Lab Med. 2008;132:1231-1240.
2. Botelho CH, Magalhaes AV, Mello PA, et al. Expression of p53, Ki- 67 and c-erb B2 in growth hormone- and/or prolactin-secreting pituitary adenomas. Arq Neuropsiquiatr. 2006;64:60-66.
3. Buckley N, Bates AS, Broome JC, et al. p53 protein accumulates in Cushing's adenomas and invasive non-functional adenomas. J Clin Endocrinol Metab. 1994;79:1513-1516. (Pubitemid 24369875)
4. Chacko G, Chacko AG, Lombardero M, et al. Clinicopathologic correlates of giant pituitary adenomas. J Clin Neurosci. 2009;16: 660-665.
5. Cho EH, Lee SA, Chung JY, et al. Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma. J Korean Med Sci. 2009;24:874-878.
6. Goel A, Nadkarni T, Muzumdar D, et al. Giant pituitary tumors: a study based on surgical treatment of 118 cases. Surg Neurol. 2004; 61:436-446.
7. Hentschel SJ, McCutcheon E, Moore W, et al. P53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas. Can J Neurol Sci. 2003;30: 215-219. (Pubitemid 37064515)
8. Kleinschmidt-DeMasters BK. Subtyping does matter in pituitary adenomas. Acta Neuropathol. 2006;111:84-85.
9. Lloyd RV, Kovacs K, Young WF Jr, et al. Tumours of the pituitary. In: DeLellis RA, Lloyd RV, Heitz PU, et al, eds. WHO Classification of Tumours-Tumours of Endocrine Organs. Lyon: IARC Press; 2004:11-12.
10. Mohr G, Hardy J, Comtois R, et al. Surgical management of giant pituitary adenomas. Can J Neurol Sci. 1990;17:62-66. (Pubitemid 20101027)
11. Oliveira MC, Marroni CP, Pizarro CB, et al. Expression of p53 protein in pituitary adenomas. Braz J Med Biol Res. 2002; 35:561-565. (Pubitemid 34568224)
12. Pernicone PJ, Scheithauer BW. Invasive pituitary adenoma and pituitary carcinoma. In: Thapar K, Kovacs K, Scheithauer BW, et al, eds. Diagnosis and Management of Pituitary Tumors. Totowa, NJ: Humana Press; 2001:369-386.
13. Pia HW, Grote E, Hildebrandt G. Giant pituitary adenomas. Neurosurg Rev. 1985;8:207-220.
14. Pizarro CB, Oliveira MC, Countinho LB, et al. Measurement of Ki- 67 antigen in 159 pituitary adenomas using the MIB-1 monoclonal antibody. Braz J Med Biol Res. 2004;37:235-243. (Pubitemid 38268156)
15. Saeger W, Lüdecke B, Lüdecke DK. Comparison of proliferation markers and clinical tumor growth in inactive adenomas. Endocr Path. 2004;15:264-265.
16. Saeger W, Ludecke DK, Buchfelder M, et al. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol. 2007;156: 203-216. (Pubitemid 46554515)
17. Schreiber S, Seager W, Ludecke DK. Proliferation markers in different types of clinically non-secreting pituitary adenomas. Pituitary. 1999;1:213-220.
18. Sinha S, Sharma BS. Giant pituitary adenomas-an enigma revisited: microsurgical treatment strategies and outcome in a series of 250 patients. Br J Neurosurg. 2010;24:31-39.
19. Suliman M, Royds J, Cullen D, et al. Mdm2 and the p53 pathway in human pituitary adenomas. Clin Endocrinol. 2001;54:317-325. (Pubitemid 32234195)
20. Thapar K, Scheithauer BW, Kovacs K, et al. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery. 1996;38:765-771. (Pubitemid 26087884)
21. Wolfsberger S, Wunderer J, Zachenhofer I, et al. Expression of cell proliferation markers in pituitary adenomas: correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha. Acta Neurochir (Wien). 2004;146:831-839.
22. Zhang X, Fei Z, Fu LA, et al. Letter: Transsphenoidal microsurgical removal of large pituitary adenomas. J Clin Neurosci. 1998;5: 474-475.
23. Zhao B, Wei YK, Li GL, et al. Extended transsphenoidal approach for pituitary adenomas invading the anterior cranial base, cavernous sinus, and clivus: a single-center experience with 126 consecutive cases. J Neurosurg. 2010;112:108-117.